These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 36631369)
1. Does care fragmentation in patients with bladder cancer lead to worse outcomes? Riveros C; Chalfant V; Elshafei A; Bandyk M; Balaji KC Urol Oncol; 2023 Mar; 41(3):147.e7-147.e14. PubMed ID: 36631369 [TBL] [Abstract][Full Text] [Related]
2. Longer time to radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes. Nuijens ST; van Osch FHM; van Hoogstraten LMC; Witjes JA; Aben KKH; Hermans TJN Urol Oncol; 2024 Apr; 42(4):117.e11-117.e16. PubMed ID: 38238116 [TBL] [Abstract][Full Text] [Related]
3. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer. Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718 [TBL] [Abstract][Full Text] [Related]
5. Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. Mitra AP; Cai J; Miranda G; Bhanvadia S; Quinn DI; Schuckman AK; Djaladat H; Daneshmand S J Urol; 2022 Feb; 207(2):302-313. PubMed ID: 34994657 [TBL] [Abstract][Full Text] [Related]
6. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841 [TBL] [Abstract][Full Text] [Related]
7. Does neoadjuvant chemotherapy diminish the sex disparity in bladder cancer survival after radical cystectomy? Venkat S; Khan AI; Taylor BL; Patel NA; Al Hussein Al Awamlh B; Calderon LP; Fainberg J; Shoag J; Scherr DS Urol Oncol; 2022 Mar; 40(3):106.e21-106.e29. PubMed ID: 34629282 [TBL] [Abstract][Full Text] [Related]
8. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival. Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752 [No Abstract] [Full Text] [Related]
9. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956 [TBL] [Abstract][Full Text] [Related]
10. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data. Lane G; Risk M; Fan Y; Krishna S; Konety B BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053 [TBL] [Abstract][Full Text] [Related]
12. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients. van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294 [TBL] [Abstract][Full Text] [Related]
13. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926 [TBL] [Abstract][Full Text] [Related]
14. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis. Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001 [TBL] [Abstract][Full Text] [Related]
15. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857 [TBL] [Abstract][Full Text] [Related]
16. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ Eur Urol Oncol; 2019 Jul; 2(4):390-396. PubMed ID: 31277775 [TBL] [Abstract][Full Text] [Related]
17. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838 [TBL] [Abstract][Full Text] [Related]
18. Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy. D'Andrea D; Shariat SF; Soria F; DI Trapani E; Mertens LS; VAN Rhijn BW; Dinney CP; Black PC; Spiess PE; Carrion DM; Pradere B; Tonin E; Pichler R; Filippot R; Mari A; Moschini M; Minerva Urol Nephrol; 2023 Aug; 75(4):452-459. PubMed ID: 37314813 [TBL] [Abstract][Full Text] [Related]
19. Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy. Sekar RR; Diamantopoulos LN; Bakaloudi DR; Khaki AR; Grivas P; Winters BR; Vakar-Lopez F; Tretiakova MS; Psutka SP; Holt SK; Gore JL; Lin DW; Schade GR; Hsieh AC; Lee JK; Yezefski T; Schweizer MT; Cheng HH; Yu EY; True LD; Montgomery RB; Wright JL Clin Genitourin Cancer; 2023 Aug; 21(4):507.e1-507.e14. PubMed ID: 37150667 [TBL] [Abstract][Full Text] [Related]
20. Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy. Chalfin HJ; Liu JJ; Gandhi N; Feng Z; Johnson D; Netto GJ; Drake CG; Hahn NM; Schoenberg MP; Trock BJ; Scott AV; Frank SM; Bivalacqua TJ Ann Surg Oncol; 2016 Aug; 23(8):2715-22. PubMed ID: 27012987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]